MedTrials is the latest participant in the Association of Clinical Research Professionals' Certification Supporting Partner Program.
MedTrials, a contract research organization, is the latest participant in the Association of Clinical Research Professionals' (ACRP) Certification Supporting Partner Program. The ACRP Certification Supporting Partner Program provides employees at partnering organizations with discounted Certification fees and exam preparation resources. Aggregate performance data is provided to partnering organizations to assist in identifying knowledge gaps of clinical research staff. The ACRP Certification Supporting Partner Program allows organizations to financially support and actively encourage eligible employees to pursue ACRP Certification and Maintenance of Certification through ACRP's Certified Clinical Research Associate (CCRA®), Certified Clinical Research Coordinator (CCRC®), and Certified Physician Investigator (CPI®) programs.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.